11/28
10:23 pm
fold
Assessing Amicus Therapeutics (FOLD) Valuation as Shares Gain 11% Over Past Month [Yahoo! Finance]
Low
Report
Assessing Amicus Therapeutics (FOLD) Valuation as Shares Gain 11% Over Past Month [Yahoo! Finance]
11/28
08:31 am
fold
How Strong Galafold and Pombiliti Sales Helped Amicus Therapeutics (FOLD) Surpass Expectations and Shift Its Outlook [Yahoo! Finance]
Low
Report
How Strong Galafold and Pombiliti Sales Helped Amicus Therapeutics (FOLD) Surpass Expectations and Shift Its Outlook [Yahoo! Finance]
11/26
02:01 pm
fold
Amicus Therapeutics (NASDAQ:FOLD) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/14
01:10 pm
fold
Amicus Therapeutics (NASDAQ:FOLD) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/11
04:59 pm
fold
Amicus Therapeutics: Moving Towards Consistent Profitability [Seeking Alpha]
Low
Report
Amicus Therapeutics: Moving Towards Consistent Profitability [Seeking Alpha]
11/10
03:40 am
fold
A Look at Amicus Therapeutics's (FOLD) Valuation After Q3 Profitability and Rare Disease Therapy Growth [Yahoo! Finance]
Medium
Report
A Look at Amicus Therapeutics's (FOLD) Valuation After Q3 Profitability and Rare Disease Therapy Growth [Yahoo! Finance]
11/10
03:01 am
fold
Zacks.com featured highlights include EverQuote, Amicus, Lam Research and Cboe Global Markets EverQuote, Amicus, Lam Research and Cboe Global Markets [Yahoo! Finance]
Medium
Report
Zacks.com featured highlights include EverQuote, Amicus, Lam Research and Cboe Global Markets EverQuote, Amicus, Lam Research and Cboe Global Markets [Yahoo! Finance]
11/6
04:27 pm
fold
Amicus Therapeutics (NASDAQ:FOLD) had its price target raised by analysts at JPMorgan Chase & Co. from $18.00 to $19.00. They now have an "overweight" rating on the stock.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) had its price target raised by analysts at JPMorgan Chase & Co. from $18.00 to $19.00. They now have an "overweight" rating on the stock.
11/5
12:25 pm
fold
Amicus Therapeutics (NASDAQ:FOLD) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $9.00 to $11.00. They now have a "neutral" rating on the stock.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $9.00 to $11.00. They now have a "neutral" rating on the stock.
11/4
07:00 am
fold
Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates
Low
Report
Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates
10/31
07:00 am
fold
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025
Low
Report
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025
10/26
01:08 am
fold
Amicus Therapeutics (NASDAQ:FOLD) was upgraded by analysts at
Wall Stree
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) was upgraded by analysts at
Wall Stree
10/25
11:32 pm
fold
Assessing Amicus Therapeutics After a 7.8% Rally and Growing Pipeline Optimism [Yahoo! Finance]
Low
Report
Assessing Amicus Therapeutics After a 7.8% Rally and Growing Pipeline Optimism [Yahoo! Finance]
10/25
01:34 pm
fold
A Fresh Look at Amicus Therapeutics (FOLD) Valuation Following Recent Share Price Momentum [Yahoo! Finance]
Low
Report
A Fresh Look at Amicus Therapeutics (FOLD) Valuation Following Recent Share Price Momentum [Yahoo! Finance]
10/23
07:00 am
fold
Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025
Low
Report
Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025
10/8
01:09 am
fold
What Does Wall Street Think About Amicus Therapeutics (FOLD)? [Yahoo! Finance]
Medium
Report
What Does Wall Street Think About Amicus Therapeutics (FOLD)? [Yahoo! Finance]
10/7
10:11 am
fold
How the Narrative Around Amicus Therapeutics Is Shifting Amid Legal and Pipeline Developments [Yahoo! Finance]
Low
Report
How the Narrative Around Amicus Therapeutics Is Shifting Amid Legal and Pipeline Developments [Yahoo! Finance]
10/6
07:49 am
fold
A Look at Amicus Therapeutics's Valuation After Analyst Upgrade and Improved Outlook (FOLD) [Yahoo! Finance]
Low
Report
A Look at Amicus Therapeutics's Valuation After Analyst Upgrade and Improved Outlook (FOLD) [Yahoo! Finance]
9/19
11:37 am
fold
Strength Seen in Amicus Therapeutics (FOLD): Can Its 6.4% Jump Turn into More Strength? [Yahoo! Finance]
Low
Report
Strength Seen in Amicus Therapeutics (FOLD): Can Its 6.4% Jump Turn into More Strength? [Yahoo! Finance]
9/18
08:09 am
fold
Amicus Therapeutics (NASDAQ:FOLD) was upgraded by analysts at Needham & Company LLC from a "hold" rating to a "buy" rating. They now have a $14.00 price target on the stock.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) was upgraded by analysts at Needham & Company LLC from a "hold" rating to a "buy" rating. They now have a $14.00 price target on the stock.
9/8
09:00 am
fold
New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM
Low
Report
New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM